Novartis
NEWS
Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures.
Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration.
Here is a look at the life science companies viewed as the most innovative in the world.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Teva and Mylan are looking over their shoulders this morning after the FDA gave Novartis and Momenta the green light for their Copaxone copycat drug.
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board.
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.
JOBS
IN THE PRESS